Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

BMYCelgeneFinished

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

3Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 2 insiders sold shares within a month

    Since Sep 9, 2026 · was worth 5, fading over time

    +2.6
Worry score3

Score over time

Stage
Phase 2
Patients
113 (final count)
Started
Jun 5, 2018
Main results expected
Dec 15, 2023
Fully finished
Dec 15, 2023
Results posted
Dec 27, 2024

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Overall Response Rate (ORR) Per Independent Review Committee in Cohorts 1, 2 and 3

    Measured over: From JCAR017 infusion until disease progression, end of study, the start of another anticancer therapy, or hemopoietic stem cell transplant (HSCT) (up to approximately 63 months)

  • Overall Response Rate (ORR) Per Investigator in Cohort 4

    Measured over: From JCAR017 infusion until disease progression, end of study, the start of another anticancer therapy, or hemopoietic stem cell transplant (HSCT) (up to approximately 63 months)

  • Overall Response Rate (ORR) Per Investigator in Cohort 5

    Measured over: From JCAR017 infusion until disease progression, end of study, the start of another anticancer therapy, or hemopoietic stem cell transplant (HSCT) (up to approximately 63 months)

  • Number of Participants With Adverse Events in Cohort 7

    Measured over: From leukapheresis to end of study (up to approximately 63 months)

  • Number of Participants With Serious Adverse Events (SAEs) in Cohort 7

    Measured over: From leukapheresis to end of study (up to approximately 63 months)

  • Number of Participants With Increase From Baseline in Select Hematology Parameters - Cohort 7

    Measured over: At Baseline and Day 29 after JCAR017 infusion

  • Number of Participants With Increase From Baseline in Select Serum Chemistry Parameters - Cohort 7

    Measured over: At Baseline and Day 29 after JCAR017 infusion

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT03484702 · record last updated 2024-12-27 · checked 2026-11-09 15:42 UTC

See the official record on ClinicalTrials.gov (NCT03484702) ↗